{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:47:46Z","timestamp":1791488866048,"version":"4.3.4"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110318","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:19:20Z","timestamp":1785737960000},"page":"110318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development of metal-free one-pot sequential synthesis of carbazolyl-thiazolidinones as anti-leukemic agents with potential \u03b2-catenin\/c-MYC pathway modulation: from synthesis to in vitro and in silico profiling"],"prefix":"10.1016","volume":"181","author":[{"given":"Syeda Aaliya","family":"Shehzadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilawar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubashir","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Kloczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman S.G.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali S.","family":"Abdelhameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110318_rf0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"7793","key":"10.1016\/j.bioorg.2026.110318_rf0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10555-024-10172-z","article-title":"Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance","volume":"43","author":"Bhat","year":"2024","journal-title":"Cancer Metastasis Rev."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110318_bb0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0098-2997(00)00007-8","article-title":"The molecular biology of cancer","volume":"21","author":"Bertram","year":"2000","journal-title":"Mol. Asp. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0030","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01563-4","article-title":"Wnt\/\u03b2-catenin signaling pathway in carcinogenesis and cancer therapy","volume":"17","author":"Song","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110318_rf0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1359-6101(00)00011-3","article-title":"Wnt\/\u03b2-catenin signaling","volume":"11","author":"Akiyama","year":"2000","journal-title":"Cytokine Growth Factor Rev."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110318_rf0040","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"issue":"6127","key":"10.1016\/j.bioorg.2026.110318_rf0045","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110318_rf0050","series-title":"Cancer: the enemy from within: a comprehensive textbook of cancer's causes, complexities and consequences","first-page":"49","article-title":"Understanding the hallmark characteristics of cancer","author":"Compton","year":"2020"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110318_rf0055","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.21873\/anticanres.14622","article-title":"Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review","volume":"40","author":"Kontomanolis","year":"2020","journal-title":"Anticancer Res."},{"issue":"7471","key":"10.1016\/j.bioorg.2026.110318_rf0060","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110318_bb0025","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1021\/acsptsci.3c00092","article-title":"Novel N-(heterocyclylphenyl) benzensulfonamide sharing an unreported binding site with t-cell factor 4 at the \u03b2-catenin armadillo repeats domain as an anticancer agent","volume":"6","author":"Nalli","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110318_bb0030","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/1535370217708198","article-title":"Discovery of small molecule inhibitors of the Wnt\/\u03b2-catenin signaling pathway by targeting \u03b2-catenin\/Tcf4 interactions","volume":"242","author":"Yan","year":"2017","journal-title":"Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0075","article-title":"Immunotherapy in hematologic malignancies: achievements, challenges and future prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110318_rf0080","article-title":"Clinical cancer immunotherapy: current progress and prospects","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110318_rf0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911526","article-title":"Therapeutic advances in immunotherapies for hematological malignancies","volume":"23","author":"Nogami","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.hoc.2019.08.020","article-title":"Hematologic malignancies","volume":"34","author":"Tseng","year":"2020","journal-title":"Hematol.\/Oncol. Clin."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0095","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-024-00239-2","article-title":"Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer","volume":"6","author":"Gu","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.bioorg.2026.110318_rf0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1366260","article-title":"Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges","volume":"15","author":"Xiang","year":"2024","journal-title":"Front. Immunol."},{"issue":"7381","key":"10.1016\/j.bioorg.2026.110318_rf0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110318_rf0110","first-page":"1","article-title":"An overview of chemotoxicity and radiation toxicity in cancer therapy","volume":"155","author":"Yazbeck","year":"2022","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110318_rf0115","series-title":"Advances in cancer treatment: from systemic chemotherapy to targeted therapy","first-page":"29","article-title":"Conventional cancer treatment","author":"Cavalcanti","year":"2021"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110318_rf0120","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/acs.chemrev.0c00383","article-title":"Challenges and opportunities in cancer drug resistance","volume":"121","author":"Ward","year":"2020","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110318_rf0125","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","article-title":"The challenge of drug resistance in cancer treatment: a current overview","volume":"35","author":"Nikolaou","year":"2018","journal-title":"Clin. Exp. Metastasis"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110318_rf0130","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000500847","article-title":"Challenges in radiotherapy","volume":"14","author":"Corradini","year":"2019","journal-title":"Breast Care (Basel)"},{"issue":"37","key":"10.1016\/j.bioorg.2026.110318_rf0135","doi-asserted-by":"crossref","first-page":"62742","DOI":"10.18632\/oncotarget.18409","article-title":"Improving radiotherapy in cancer treatment: promises and challenges","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110318_rf0140","series-title":"Hall EJ. Radiobiology for the radiologist","author":"Park","year":"2006"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0145","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01801-2","article-title":"Molecular mechanisms of tumor resistance to radiotherapy","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110318_rf0150","doi-asserted-by":"crossref","first-page":"26880","DOI":"10.3390\/ijms161125991","article-title":"Therapeutic implications for overcoming radiation resistance in cancer therapy","volume":"16","author":"Kim","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies\u2014a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110318_rf0160","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215456","article-title":"Targeted therapy and immunotherapy for heterogeneous breast cancer","volume":"14","author":"Sun","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10549-015-3383-6","article-title":"A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer","volume":"151","author":"Diaby","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110318_rf0170","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","article-title":"Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer","volume":"22","author":"Labrie","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110318_bb0065","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cllc.2017.02.001","article-title":"Immune checkpoint inhibitors for patients with advanced non\u2013small-cell lung cancer: a systematic review","volume":"18","author":"Ellis","year":"2017","journal-title":"Clin. Lung Cancer"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110318_rf0180","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/1060028015586218","article-title":"Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology","volume":"49","author":"Barbee","year":"2015","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110318_rf0185","doi-asserted-by":"crossref","DOI":"10.1002\/chir.70021","article-title":"A review on carbazole and its derivatives as anticancer agents from 2013 to 2024","volume":"37","author":"Waghmare","year":"2025","journal-title":"Chirality"},{"key":"10.1016\/j.bioorg.2026.110318_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108689","article-title":"Fluorenyl-phthalimide hybrids as potent aldose reductase inhibitors with selective anticancer activity: rational design, synthesis, and molecular insights","volume":"163","author":"Gundogdu","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110318_bb0080","doi-asserted-by":"crossref","first-page":"108861","DOI":"10.1016\/j.bioorg.2025.108861","article-title":"Chalcone-inspired indole, carbazole, and phenothiazine hybrids as potent aldose reductase inhibitors with selective anticancer potential: rational design, synthesis, and multi-level characterization","volume":"164","author":"G\u00fcle\u00e7","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110318_rf0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118416","article-title":"Phthalimide\u2013benzoic acid hybrids as potent aldose reductase inhibitors: synthesis, enzymatic kinetics, and in silico characterization","author":"Hoti","year":"2025","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0205","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1039\/D4MD00617H","article-title":"Novel benzenesulfonamides containing a dual triazole moiety with selective carbonic anhydrase inhibition and anticancer activity","volume":"16","author":"Buza","year":"2025","journal-title":"RSC Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0210","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bmc.2017.11.044","article-title":"Studies on interactions of carbazole derivatives with DNA, cell image, and cytotoxicity","volume":"26","author":"Hao","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110318_rf0215","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/cmdc.201600391","article-title":"Carbazole aminoalcohols induce antiproliferation and apoptosis of human tumor cells by inhibiting topoisomerase I","volume":"11","author":"Wang","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.110318_rf0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113999","article-title":"Current status of carbazole hybrids as anticancer agents","volume":"229","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110318_bb0095","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2174\/1389557520666200117144701","article-title":"Carbazole derivatives as kinase-targeting inhibitors for cancer treatment","volume":"20","author":"Ceramella","year":"2020","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110318_rf0230","first-page":"1","article-title":"Thiazolidinedione derivatives: emerging role in cancer therapy","author":"Latambale","year":"2025","journal-title":"Mol. Divers."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110318_rf0235","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.2174\/1871520622666220404082648","article-title":"Heterocyclic compounds: importance in anticancer drug discovery","volume":"22","author":"Kumar","year":"2022","journal-title":"Anti-Cancer Agents Med. Chem. Anti-Cancer Agents"},{"key":"10.1016\/j.bioorg.2026.110318_rf0240","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cbi.2016.12.008","article-title":"Study of novel anticancer 4-thiazolidinone derivatives","volume":"262","author":"Szychowski","year":"2017","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.110318_rf0245","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ejmech.2014.10.025","article-title":"Thiazolidine-2, 4-diones as multi-targeted scaffold in medicinal chemistry: potential anticancer agents","volume":"87","author":"Asati","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110318_rf0250","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400576","article-title":"Insight into the therapeutic potential of pyrazole-thiazole hybrids: a comprehensive review","volume":"357","author":"Sumran","year":"2024","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110318_rf0255","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejmech.2019.03.024","article-title":"Multi-target compounds acting in cancer progression: focus on thiosemicarbazone, thiazole and thiazolidinone analogues","volume":"170","author":"de Siqueira","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110318_bb0110","doi-asserted-by":"crossref","first-page":"8630","DOI":"10.1021\/jm300789g","article-title":"Synthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activity","volume":"55","author":"Havrylyuk","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110318_bb0115","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejmech.2016.10.018","article-title":"Synthesis and evaluation of novel hybrids \u03b2-carboline-4-thiazolidinones as potential antitumor and antiviral agents","volume":"124","author":"Barbosa","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110318_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103904","article-title":"Targeted photoresponsive carbazole\u2013coumarin and drug conjugates for efficient combination therapy in leukemia cancer cells","volume":"100","author":"Wang","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110318_bb0125","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1080\/10406638.2022.2039231","article-title":"Access to a library of 3-(9-methyl-9H-carbazol-3-yl)-2-arylthiazolidin-4-one derivatives using NiFe2O4@ SiO2grafted alkyl sulfonic acid as an efficient catalyst","volume":"43","author":"Hajiarab","year":"2023","journal-title":"Polycycl. Aromat. Compd."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110318_bb0130","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/jhet.1047","article-title":"One-pot three-component mild synthesis of 2-Aryl-3-(9-alkylcarbazol-3-yl) thiazolidin-4-ones","volume":"49","author":"Li","year":"2012","journal-title":"J. Heterocyclic Chem."},{"issue":"41","key":"10.1016\/j.bioorg.2026.110318_bb0135","article-title":"Targeting Musashi-2 to counteract senescence and resistance in chronic myeloid leukemia: enhancing the efficacy of imatinib therapy","volume":"26","author":"Khadija Arif","year":"2026","journal-title":"BMC Cancer"},{"issue":"713","key":"10.1016\/j.bioorg.2026.110318_bb0140","article-title":"AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia","volume":"21","author":"Mariam Fatima","year":"2021","journal-title":"BMC Cancer"},{"issue":"1944","key":"10.1016\/j.bioorg.2026.110318_rf0295","article-title":"TAM family kinases are potential candidate targets for therapeutic intervention in chronic myeloid leukemia","volume":"16","author":"Maryam Yousaf","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0300","article-title":"An update to DNA ladder assay for apoptosis detection","volume":"5","author":"Saadat","year":"2015","journal-title":"Bioimpacts"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110318_bb0150","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0310","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jcc.21600","article-title":"Gabedit-A graphical user interface for computational chemistry softwares","volume":"32","author":"Allouche","year":"2011","journal-title":"J. Comput. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110318_rf0315","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.110318_bb0160","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.aim.2014.05.019","article-title":"Capillary surfaces with free boundary in a wedge","volume":"262","author":"L\u00f3pez","year":"2014","journal-title":"Adv. Math."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110318_bb0165","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein\u2013ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"Forli","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bioorg.2026.110318_bb0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110318_rf0335","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM-GUI: a web-based graphical user interface for CHARMM","volume":"29","author":"Jo","year":"2008","journal-title":"J. Comput. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110318_rf0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpj.2015.11.3431","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"110","author":"Lee","year":"2016","journal-title":"Biophys. J."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_bb0180","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"25","key":"10.1016\/j.bioorg.2026.110318_bb0185","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jcc.23354","article-title":"CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data","volume":"34","author":"Huang","year":"2013","journal-title":"J. Comput. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110318_bb0190","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110318_bb0195","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/prot.22711","article-title":"Improved side-chain torsion potentials for the Amber ff99SB protein force field","volume":"78","author":"Lindorff-Larsen","year":"2010","journal-title":"Proteins: Struct., Funct., Bioinf."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110318_bb0200","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: AN N log (N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110318_bb0205","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"LINCS: A linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J. Comput. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110318_bb0210","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular dynamics simulation for all","volume":"99","author":"Hollingsworth","year":"2018","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110318_rf0380","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/jccs.201700061","article-title":"Cu (I)-catalyzed green synthesis of propargyl amines decorated with carbazole moiety by A3-coupling","volume":"64","author":"Shehzadi","year":"2017","journal-title":"J. Chin. Chem. Soc."},{"issue":"22","key":"10.1016\/j.bioorg.2026.110318_rf0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115123","article-title":"Developing new hybrid scaffold for urease inhibition based on carbazole-chalcone conjugates: synthesis, assessment of therapeutic potential and computational docking analysis","volume":"27","author":"Kazmi","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110318_bb0220","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1038\/sj.onc.1205400","article-title":"The proto-oncogene c-myc in hematopoietic development and leukemogenesis","volume":"22","author":"Barbara Hoffman","year":"2002","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_rf0395","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a020990","article-title":"MYC and transcription elongation","volume":"4","author":"Rahl","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"7152","key":"10.1016\/j.bioorg.2026.110318_rf0400","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature05953","article-title":"Non-transcriptional control of DNA replication by c-Myc","volume":"448","author":"Dominguez-Sola","year":"2007","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110318_rf0405","first-page":"1453","article-title":"Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc","volume":"6","author":"Denis","year":"1991","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110318_rf0410","doi-asserted-by":"crossref","DOI":"10.3390\/biom7030053","article-title":"MYC-driven pathways in breast cancer subtypes","volume":"7","author":"Fallah","year":"2017","journal-title":"Biomolecules"},{"issue":"03","key":"10.1016\/j.bioorg.2026.110318_rf0415","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/BS9.0000000000000073","article-title":"MYC in T-cell acute lymphoblastic leukemia: functional implications and targeted strategies","volume":"3","author":"Li","year":"2021","journal-title":"Blood Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110318_bb0230","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1128\/MCB.24.7.2890-2904.2004","article-title":"Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells","volume":"24","author":"M\u00fcller-Tidow","year":"2004","journal-title":"Mol. Cell. Biol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110318_bb0235","article-title":"Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells","volume":"24","author":"Carsten M\u00fcller-Tidow","year":"2004","journal-title":"Mol. Cell. Biol."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110318_bb0240","article-title":"Kaempferol enhances cisplatin\u2019s effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc","volume":"10","author":"Haitao Luo","year":"2010","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bioorg.2026.110318_bb0245","article-title":"The dynamic process of apoptosis analyzed by flow cytometry using annexin-V\/propidium iodide and a modified in situ end labeling technique","volume":"47","author":"Span","year":"2002","journal-title":"J. Quant. Cell Sci."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110318_bb0250","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/17460441.2023.2275617","article-title":"Evaluating physiochemical properties of FDA-approved orally administered drugs","volume":"19","author":"Reese","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_bb0255","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110318_rf0455","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014241","article-title":"MYC activation is a hallmark of cancer initiation and maintenance","volume":"4","author":"Gabay","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110318_rf0460","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_bb0265","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/ijms20010120","article-title":"Therapeutic inhibition of Myc in cancer. Structural bases and computer-aided drug discovery approaches","volume":"20","author":"Carabet","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110318_bb0270","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0092-8674(84)90209-5","article-title":"Structure and nucleotide sequence of the putative mammary oncogene int-1; proviral insertions leave the protein-encoding domain intact","volume":"39","author":"van Ooyen","year":"1984","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110318_rf0475","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ceb.2007.02.007","article-title":"Wnt\/\u03b2-catenin signaling in cancer stemness and malignant behavior","volume":"19","author":"Fodde","year":"2007","journal-title":"Curr. Opin. Cell Biol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110318_rf0480","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1053\/j.gastro.2015.02.056","article-title":"\u03b2-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis","volume":"148","author":"Monga","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110318_bb0280","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/bib\/2.2.199","article-title":"Molecular modelling: principles and applications","volume":"6","author":"Valverde","year":"2001","journal-title":"Brief. Bioinform."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110318_bb0285","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1021\/jp508971m","article-title":"Water dispersion interactions strongly influence simulated structural properties of disordered protein states","volume":"119","author":"Piana","year":"2015","journal-title":"J. Phys. Chem. B"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110318_bb0290","doi-asserted-by":"crossref","DOI":"10.1063\/1.4960175","article-title":"Accuracy limit of rigid 3-point water models","volume":"145","author":"Izadi","year":"2016","journal-title":"J. Chem. Phys."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:06:31Z","timestamp":1791407191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":98,"alternative-id":["S0045206826008540"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110318","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of metal-free one-pot sequential synthesis of carbazolyl-thiazolidinones as anti-leukemic agents with potential \u03b2-catenin\/c-MYC pathway modulation: from synthesis to in vitro and in silico profiling","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110318"}}